EcoDrugPlus

C-X-C Motif Chemokine Receptor 2

Ensembl ID : ENSUPAG00010011661
Gene Symbol: CXCR2
3 Cross references
237 Possible Orthologues:

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSUPAG00010005161
Gene Symbol: CXCR4
3 Cross references
283 Possible Orthologues:

C-Type Lectin Domain Family 4 Member A-Like

Ensembl ID : ENSUPAG00010020655
Gene Symbol: LOC113201635
2 Cross references
731 Possible Orthologues:

Dna Methyltransferase 1

Ensembl ID : ENSUPAG00010000182
Gene Symbol: DNMT1
1 Cross references
206 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSUPAG00010002274
Gene Symbol: TOP1
1 Cross references
270 Possible Orthologues:

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSUPAG00010008363
Gene Symbol: TOP2A
3 Cross references
209 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSUPAG00010001529
Gene Symbol: TOP2B
3 Cross references
208 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSUPAG00010007608
Gene Symbol: EML4
1 Cross references
209 Possible Orthologues:

Eph Receptor A2

Ensembl ID : ENSUPAG00010017996
Gene Symbol: EPHA2
3 Cross references
124 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSUPAG00010021738
Gene Symbol: EPHA3
3 Cross references
215 Possible Orthologues:

Eph Receptor B4

Ensembl ID : ENSUPAG00010017548
Gene Symbol: EPHB4
3 Cross references
166 Possible Orthologues:

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSUPAG00010021628
Gene Symbol: F2RL3
1 Cross references
197 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).